High hopes for US cannabis businesses | DW News

Key Concepts

• Schedule I Drug: A classification under the Controlled Substances Act with no accepted medical use and a high potential for abuse (e.g., heroin, LSD).
• Schedule III Drug: A classification with accepted medical use and moderate to low potential for abuse (e.g., steroids, painkillers with codeine).
• Rescheduling: The process of moving a drug to a different schedule under the Controlled Substances Act.
• Decriminalization: Reducing penalties for possession of a substance, often to a fine rather than jail time.
• Legalization: Removing all prohibitions on the production, sale, and possession of a substance.
• CBD (Cannabidiol): A non-psychoactive compound found in cannabis.

Executive Order & Cannabis Rescheduling

President Donald Trump signed an executive order initiating the process of rescheduling cannabis at the federal level. This action aims to move cannabis from Schedule I to Schedule III under the Controlled Substances Act of 1970. Currently, cannabis is categorized alongside drugs like heroin and LSD, signifying no accepted medical use and a high potential for abuse. The proposed rescheduling would place it with substances like steroids and painkillers containing codeine, indicating accepted medical applications and a lower potential for abuse. The President stated the decision was driven by public demand, specifically “people begging for me to do this, people that are in great pain.”

Historical Context & Current Legal Landscape

Cannabis has been classified as a Schedule I drug since 1971. This classification has significantly hindered research into its potential medical benefits and created substantial legal and financial obstacles for cannabis businesses. Despite the federal prohibition, over half of US states have already legalized or decriminalized cannabis to varying degrees, creating a complex legal conflict between state and federal laws. This discrepancy leaves cannabis companies vulnerable to federal enforcement actions and facing difficulties accessing traditional banking services.

Market Reaction & Limitations of the Order

Initial market reaction to the announcement was positive, with cannabis-related stocks experiencing a surge. However, these gains were quickly lost due to the absence of provisions addressing cannabis banking. This highlights the continued speculative nature of the cannabis market. It’s crucial to note, as stated in the report, “It doesn't legalize marijuana in any way, shape, or form.” Federal law still prohibits marijuana, and the executive order does not change that fundamental fact.

Potential Impacts of Rescheduling

Rescheduling cannabis to Schedule III is expected to have several positive impacts:

• Reduced Tax Burden: Cannabis companies currently face significant tax disadvantages due to Section 280E of the Internal Revenue Code, which prohibits businesses trafficking in Schedule I or II substances from deducting normal business expenses. Rescheduling could alleviate this burden.
• Increased Investment: A less restrictive classification is anticipated to encourage further investment in the cannabis sector.
• Facilitated Medical Research: Rescheduling will simplify the process of conducting medical research on cannabis and its potential therapeutic applications.
• CBD Reimbursement Pilot Program: The new regulations pave the way for a pilot program to reimburse Medicare patients for products containing CBD.

Market Size & Future Growth

The cannabis market currently generates approximately $32 billion annually. While the executive order doesn’t represent full legalization, it is projected to stimulate significant growth within the industry. The report emphasizes that this action “could spark up major growth for a market which already generates $32 billion annually.”

Logical Connections & Synthesis

The executive order represents a significant, albeit incremental, step towards federal cannabis reform. The core issue is the conflict between state legalization/decriminalization and federal prohibition. Rescheduling addresses some of the practical challenges faced by the industry – particularly regarding taxation and research – but does not resolve the fundamental legal ambiguity. The lack of banking reform underscores the need for further legislative action. Ultimately, the order’s impact will depend on the speed and effectiveness of the rescheduling process and whether it prompts further federal action on cannabis policy.